Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single Centre experience of 12 cases.

Conclusions: The introduction or the switch to Rixathon, a rituximab biosimilar, appears to be safe and may provide an opportunity to reduce health system costs because of its similarity to the reference drug in terms of safety and efficacy. PMID: 32068447 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32068447?dopt=Abstract

Source: Journal of Dermatological Treatment - February 19, 2020 Category: Dermatology Tags: J Dermatolog Treat Source Type: research